FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223596871> ?p ?o ?g. }

• W4223596871 endingPage "152004" @default.
• W4223596871 startingPage "152004" @default.
• W4223596871 abstract "The clinical heterogeneity of the progression of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is high, and there is a lack of consensus on the clinical relevance and medical protocols. The purpose of this study is to explore the impact of clinical characteristics, new biomarkers and treatment options on the prognosis of RA-ILD patients and to explore whether these factors can predict the progression and death of these patients. We retrospectively collected case data on RA-ILD patients who visited or were admitted to Changhai Hospital between October 2010 and September 2021. We followed up and finally included 75 patients. The main outcome indicator of disease progression was pulmonary functional impairment, which was assessed by changes of high-resolution computed tomography (HRCT) score or pulmonary function test before and after treatment. The demographics, clinical characteristics, laboratory tests, and treatment plans of RA-ILD patients in the progressive and stable groups were compared and analyzed. Clinically relevant variables were identified, and the incidence of pulmonary dysfunction and adverse events was recorded. Cox regression analysis was used to determine factors related to the progression of ILD. The mean age of RA-ILD onset was 64.0 years (SD 10.3), and 53 (70.7%) patients were female. Thirty-two (42.7%) patients had lung dysfunction, who were classified as the progressive group, and 13 (40.6%) of them died. In univariate analyses, male, smoking, high HRCT scores at baseline, RF-IgA>200 RU/ml, diffusing capacity of the lungs for carbon monoxide (DLCO), and usual interstitial pneumonia (UIP) pattern were significant risk factors for disease progression; while use of Leflunomide (LEF) was associated with better prognosis. The multivariate analysis revealed that RF-IgA>200 RU/ml (hazard ratio [HR] 3.17 [95% confidence interval (CI) 1.29, 7.81], P = 0.012), UIP pattern (HR 3.94 [95% CI 1.68, 9.26], P = 0.002), and male (HR 2.52 [95% CI 1.16, 5.46], P = 0.019) were significantly correlated with unfavorable outcomes in patients with RA-ILD. LEF (HR 0.25 [95% CI 0.10, 0.61], P = 0.002) was related to a better prognosis. However, it might be related to investigating medications changes after baseline. Our data suggests that male, UIP pattern, and increased RF-IgA may be potential predicting factors for poor prognosis of RA-ILD patients. We report a significant association between high titer of RF-IgA at baseline and RA-ILD progression for the first time, which might be a potentially important biomarker for the prognosis of RA-ILD." @default.
• W4223596871 created "2022-04-15" @default.
• W4223596871 creator A5018406452 @default.
• W4223596871 creator A5042975008 @default.
• W4223596871 creator A5049999897 @default.
• W4223596871 creator A5066565410 @default.
• W4223596871 date "2022-08-01" @default.
• W4223596871 modified "2023-10-16" @default.
• W4223596871 title "Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: Clinical features, biomarkers, and treatment options" @default.
• W4223596871 cites W1737953065 @default.
• W4223596871 cites W1910502462 @default.
• W4223596871 cites W1921974465 @default.
• W4223596871 cites W1974141152 @default.
• W4223596871 cites W2017839708 @default.
• W4223596871 cites W2021354645 @default.
• W4223596871 cites W2024988150 @default.
• W4223596871 cites W2030895086 @default.
• W4223596871 cites W2042096696 @default.
• W4223596871 cites W2042342145 @default.
• W4223596871 cites W2077659453 @default.
• W4223596871 cites W2080474577 @default.
• W4223596871 cites W2095657111 @default.
• W4223596871 cites W2096455579 @default.
• W4223596871 cites W2100169944 @default.
• W4223596871 cites W2102722254 @default.
• W4223596871 cites W2110826367 @default.
• W4223596871 cites W2113377455 @default.
• W4223596871 cites W2113822003 @default.
• W4223596871 cites W2122336434 @default.
• W4223596871 cites W2128952811 @default.
• W4223596871 cites W2130829606 @default.
• W4223596871 cites W2133103918 @default.
• W4223596871 cites W2134374416 @default.
• W4223596871 cites W2152348310 @default.
• W4223596871 cites W2197347269 @default.
• W4223596871 cites W2253928782 @default.
• W4223596871 cites W2337898304 @default.
• W4223596871 cites W2339383202 @default.
• W4223596871 cites W2361358989 @default.
• W4223596871 cites W2440054067 @default.
• W4223596871 cites W2510667178 @default.
• W4223596871 cites W2547162863 @default.
• W4223596871 cites W2608504023 @default.
• W4223596871 cites W2624537152 @default.
• W4223596871 cites W2626574050 @default.
• W4223596871 cites W2769043446 @default.
• W4223596871 cites W2794372383 @default.
• W4223596871 cites W2806460375 @default.
• W4223596871 cites W2886363262 @default.
• W4223596871 cites W2896189647 @default.
• W4223596871 cites W2896936897 @default.
• W4223596871 cites W2996104883 @default.
• W4223596871 cites W3003324155 @default.
• W4223596871 cites W3003676627 @default.
• W4223596871 cites W3024779281 @default.
• W4223596871 cites W3028055151 @default.
• W4223596871 cites W3041647848 @default.
• W4223596871 cites W3048689021 @default.
• W4223596871 cites W3081522071 @default.
• W4223596871 cites W3093381665 @default.
• W4223596871 cites W3131723882 @default.
• W4223596871 cites W3152718575 @default.
• W4223596871 cites W3174527541 @default.
• W4223596871 cites W3193797524 @default.
• W4223596871 doi "https://doi.org/10.1016/j.semarthrit.2022.152004" @default.
• W4223596871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35472663" @default.
• W4223596871 hasPublicationYear "2022" @default.
• W4223596871 type Work @default.
• W4223596871 citedByCount "7" @default.
• W4223596871 countsByYear W42235968712023 @default.
• W4223596871 crossrefType "journal-article" @default.
• W4223596871 hasAuthorship W4223596871A5018406452 @default.
• W4223596871 hasAuthorship W4223596871A5042975008 @default.
• W4223596871 hasAuthorship W4223596871A5049999897 @default.
• W4223596871 hasAuthorship W4223596871A5066565410 @default.
• W4223596871 hasConcept C126322002 @default.
• W4223596871 hasConcept C144301174 @default.
• W4223596871 hasConcept C16020263 @default.
• W4223596871 hasConcept C165637977 @default.
• W4223596871 hasConcept C2776232647 @default.
• W4223596871 hasConcept C2777524225 @default.
• W4223596871 hasConcept C2777543607 @default.
• W4223596871 hasConcept C2777575956 @default.
• W4223596871 hasConcept C2777714996 @default.
• W4223596871 hasConcept C3018587741 @default.
• W4223596871 hasConcept C38180746 @default.
• W4223596871 hasConcept C55520419 @default.
• W4223596871 hasConcept C71924100 @default.
• W4223596871 hasConcept C75603125 @default.
• W4223596871 hasConceptScore W4223596871C126322002 @default.
• W4223596871 hasConceptScore W4223596871C144301174 @default.
• W4223596871 hasConceptScore W4223596871C16020263 @default.
• W4223596871 hasConceptScore W4223596871C165637977 @default.
• W4223596871 hasConceptScore W4223596871C2776232647 @default.
• W4223596871 hasConceptScore W4223596871C2777524225 @default.
• W4223596871 hasConceptScore W4223596871C2777543607 @default.
• W4223596871 hasConceptScore W4223596871C2777575956 @default.
• W4223596871 hasConceptScore W4223596871C2777714996 @default.

• next